Mission Statement, Vision, & Core Values (2026) of Tempus AI, Inc.

Founded in 2015 by Eric Lefkofsky and headquartered in Chicago, Tempus AI, Inc. is building a data-first healthcare engine that leverages artificial intelligence to support clinicians in oncology, cardiology, radiology and depression-spanning 4 core diagnostic areas-while growing a global footprint with offices in New York, San Francisco and London; the company, which went public on the Nasdaq on June 14, 2024 under the ticker TEM, employs roughly 2,300 people and centers its mission on bringing technology, data and AI to doctors to help them make better decisions so patients live longer and healthier lives, guided by a vision to democratize clinical and molecular data for precision medicine at scale and grounded in core values of Integrity, Innovation, Collaboration, Excellence and Community Engagement.

Tempus AI, Inc. (TEM) - Intro

• Founded: 2015 (Founder: Eric Lefkofsky)
• Headquarters: Chicago, IL
• Public listing: Nasdaq - TEM (June 14, 2024)
• Employees (2024): ~2,300
• Global offices: Chicago, New York, San Francisco, London, and others

• Data-driven clinical decision support
• Scalable diagnostics across disease areas
• Bridging genomic, imaging, and clinical data for personalized care

• Integrating multi-modal data (genomics, imaging, EHR) at scale
• Delivering validated AI models that inform care pathways
• Global expansion to increase access to precision diagnostics

• Patient-first orientation: prioritize outcomes and safety in product design
• Scientific rigor: evidence-based model development and validation
• Data stewardship: privacy, security, and ethical use of clinical data
• Collaboration: partnerships with providers, researchers, and payers
• Continuous innovation: iterative improvement of algorithms and assays

• Clinical integration: deployment of diagnostics and AI tools across multiple provider systems (oncology and beyond)
• Product breadth: molecular sequencing, imaging analytics, clinical decision support, and depression diagnostics
• Research partnerships: collaborations with academic centers and pharmaceutical companies to accelerate therapeutic development

Tempus AI, Inc. (TEM) - Overview

Tempus AI's mission is to bring the power of technology, data, and AI to doctors by building a leading precision medicine platform in the world-ultimately helping doctors make better decisions and help ensure patients live longer and healthier lives. This mission centers Tempus on integrating genomic, clinical, and molecular data with machine learning to deliver actionable insights at the point of care, accelerate research, and personalize therapy selection.

• Precision medicine focus: tailoring diagnostics and treatments to individual patients using multimodal data (genomic, clinical, imaging, and outcomes).
• Clinician enablement: tools and analytics designed to improve diagnostic confidence, treatment selection, and care-path decisions.
• Patient-centric outcomes: prioritizing longer, healthier lives through earlier detection, optimized therapy, and evidence-driven care.

Key operational and impact metrics (publicly reported and widely cited):

Vision

Tempus envisions a healthcare system where every clinician has fast, reliable access to integrated molecular and clinical intelligence so that each patient receives precisely the therapy most likely to benefit them. The company aims to create an interoperable, learning health ecosystem in which aggregated, de-identified real-world data and validated AI models continuously improve diagnostic accuracy, clinical trials matching, and therapeutic outcomes.

• Scale AI-enabled decision support across oncology and other specialties.
• Shorten time-to-treatment with actionable, reportable insights at point-of-care.
• Accelerate drug development by providing richer molecular datasets for clinical trial design and biomarker discovery.

Core Values

• Patient-first orientation: prioritize interventions and products that demonstrably improve patient outcomes and quality of life.
• Clinical partnership: co-develop solutions with clinicians to ensure utility, usability, and clinical relevance.
• Data integrity and security: maintain rigorous standards for data quality, privacy, and regulatory compliance when handling sensitive health information.
• Scientific rigor: validate models and assays through peer-reviewed science, clinical validation studies, and continuous performance monitoring.
• Transparency and collaboration: share learnings with the research and clinical communities, enabling broader advances in precision medicine.
• Operational excellence: invest in reproducible processes, scalable infrastructure, and measurable clinical workflows to deliver reliable, timely results.

Financial and market context shaping mission execution:

• Large addressable market: oncology diagnostics and precision therapeutics represent tens of billions in annual spend worldwide; precision diagnostics adoption continues to grow year-over-year.
• Capital and investment: >$1B+ of private capital historically enabled rapid platform build-out, large-scale sequencing operations, and commercial expansion.
• Revenue and commercialization: rapid commercialization efforts centered on diagnostic testing, informatics subscriptions for health systems and life-science partnerships, and data licensing for research and drug development.

How mission translates to measurable actions and milestones:

• Expanding sequencing throughput and reducing turnaround times to deliver clinically actionable reports within targeted windows for oncology decision-making.
• Deploying validated AI models into clinician workflows, measuring impact on treatment selection concordance, trial enrollment rates, and downstream outcomes.
• Growing curated, de-identified datasets that enable pharma partners to accelerate biomarker discovery and trial cohort identification.

Further detail on company positioning, investor interest, and stakeholder activity can be explored here: Exploring Tempus AI, Inc. Investor Profile: Who's Buying and Why?

Tempus AI, Inc. (TEM): Mission Statement

• Democratize access: Reduce barriers to advanced clinical and molecular data so community hospitals, academic centers, and underserved populations can benefit from precision medicine.
• Scale precision medicine: Move beyond niche clinical trials to operationalize personalized treatment decisions across millions of patients.
• AI & ML-first: Continuously invest in machine learning models trained on multimodal datasets (genomics, pathology, EHR, imaging) to improve predictive performance and clinical utility.

• Data scale: Curate and analyze a multimodal dataset comprising clinical records, molecular sequencing, and imaging from over one million patient encounters (institutional reporting indicates datasets in the high six- to low seven-figure patient range).
• Lab capacity and diagnostics: Maintain CLIA-certified and CAP-accredited laboratory operations designed to support high-throughput sequencing and companion diagnostics for oncology and other indications.
• Commercial and research reach: Partner with hundreds of hospitals, health systems, and biopharma companies to support clinical decision support, trial matching, and biomarker discovery.
• Financing & investment: Secure institutional capital to scale operations and R&D - cumulative private funding rounds and growth capital exceed $1 billion, supporting technology development and lab expansion.

• Platform development: Prioritize interoperable AI models that integrate EHR, genomic, and imaging data to support end-to-end clinical workflows (diagnosis → therapy selection → outcomes tracking).
• Access focus: Build commercial models and cloud-enabled services to extend diagnostics and decision support to community oncology practices and underserved regions.
• Evidence generation: Use large-scale real-world data to validate AI models and biomarkers, accelerating regulatory submissions and payer coverage discussions.
• Collaborative research: Engage biopharma and academic partners in co-development of companion diagnostics and trial enrichment strategies to shorten drug development cycles.

• Reduce time-to-decision for targeted therapy selection by shortening turnaround from weeks to days through optimized sequencing and reporting pipelines.
• Increase trial enrollment efficiency by employing AI-driven molecular matching to identify eligible patients across partner sites, improving match rates and reducing site burden.
• Expand equitable access by deploying affordable, interpretable diagnostics and decision support in non-academic settings, aiming to grow coverage beyond major centers.

Tempus AI, Inc. (TEM) - Vision Statement

• Integrity - honesty, accountability, and ethical behavior in data stewardship, clinical partnerships, and business conduct.
• Innovation - relentless investment in AI, machine learning, genomics, and multi-omic analytics to transform diagnostics and therapeutics.
• Collaboration - cross-disciplinary work with academic centers, health systems, biopharma, and payers to translate data into actionable care.
• Excellence - rigorous quality control, regulatory compliance, and clinical validation to meet high standards across assays, software, and services.
• Community Engagement - programs and partnerships that expand access, support underrepresented populations, and return value to patients and clinicians.

• Data governance and integrity: HIPAA compliance, de-identification protocols, and institutional review board (IRB) partnerships to maintain ethical standards and trust.
• Clinical validation: peer-reviewed studies and CLIA/CAP-accredited laboratory processes that uphold excellence in diagnostic performance.
• Access and equity initiatives: targeted community programs, discounting or grant-supported testing pathways, and collaborations to reduce disparities.

• Integrity → Expand compliance frameworks, transparent reporting, and patient consent models.
• Innovation → Scale multi-omic platforms, deploy federated learning, and accelerate AI model validation.
• Collaboration → Deepen strategic alliances with oncology networks, community hospitals, and pharmaceutical partners.
• Excellence → Strengthen lab throughput, turn-around-time targets, and quality assurance metrics.
• Community Engagement → Increase funded programs that broaden access; measure impact by outreach and uptake metrics.